Resp Paces Flashcards
Clinical signs of a lobectomy
Posterolateral thoracotomy scar or 3 scars (1 x 10cm in length + 2 port scars)
Reduced expansion and chest wall deformity
Lower lobectomy: dull percussion note over lower zone with absent breath sounds
Upper lobectomy: normal examination or hyperresonant percussion note over upper zone and dull base
CXR: raised hemidiaphragm
Ct chest
Indication for VATS
Lobectomy mainly for malignancy
Wedge resection for benign pathology
Bullectomy for recurrent pneumothoracices
Biopsy
Primary vs secondary spontaneous pneumothorax
Primary: no underlying lung disease, normally occurs in tall, slim men, smoker
Secondary: associated with underlying lung disease
Management of primary spontaneous pneumothorax
If asymptomatic and <2cm: supplementary O2 follow up CXR
If breathless or >2cm:
Supplementary O2, aspiration, if aspiration fails need chest drain
Management of secondary pneumothorax
If < 1cm and no breathlessness: supplementary O2, observe in hospital
If 1-2cm and no breathlessness: O2, aspirate, drain
If >2cm or symptomatic: O2, chest drain
Management of tension pneumothorax
Oxygen
Emergency needle decompression 2nd ICS mid clavicular line or midaxillary line 4th/5th ICS
Management of recurrent pneumothoracices or air leak
Bullectomy if Bullae present
Pleurectomy or talc pleurodesis
Advice to give patient post pneumothorax
Avoid air travel until full resolution
Avoid diving permanently unless has had bilateral surgical pleurectomy and normal lung function tests and Ct chest post- operatively
Risk factors for asthma
Cigarette smoke
Fumes
Work place exposure
Personal/family history of atopy
Resp infection in childhood
Obesity
Triggers for asthma exacerbation
Exercise
Infection
GORD
Drugs- aspirin, NSAIDs, b blockers
Poor medication compliance
Cold weather
Signs of chronic asthma
Tachypnoea
Wheezing
Hyperinflated chest
Nasal polyps
Atopic eczema
Diagnosis of asthma
History
Examination findings
Spirometry
- increased lung volumes
- Reduced FEV1
FEV1:FVC ratio <70%
- reversibility (at least 200ml)
Peak Flow diary
- >20% diurnal variability
- may also identify occupational asthma
- > 15% improvement with bronchodilator
FeNO
- conforms eosinophilic airway inflammation (FeNO level > 40 is positive in steroid naive adults)
Eosinophilia
Skin prick testing
Non pharmacological management of asthma
Education
- Weight loss
- Smoking cessation
- Inhaler training
Monitoring / follow up
- Peak flow monitoring
- Annual follow up
- Vaccination
Medical treatment of asthma
- Salbutamol prn + low dose ICS
- LABA [long acting bronchodilator] + ICS
- Increase ICS dose + LABA + LTRA [leukotrine receptor antagonist]
- Specialist care
Moderate acute asthma
Sats > 92%
PEFR >50%
No signs of severe
Acute severe asthma
Sats >92
Can’t talk in full sentences
HR >110
RR>25
Peak flow 33-50%
Life threatening asthma
Sats <92
Silent chest
Poor resp effort
Exhaustion
Confusion
Cyanosis
Near fatal asthma
Raised pCO2
Management of asthma exacerbation
Nebs
Steroids
O2
Antibiotics if infection
Magnesium
Aminophylline
Monitor peak flows
Refer to ICU if deteriorating PEFR, worsening hypoxia, rising CO2/acidosis, exhaustion, altered consciousness
Criteria for discharging asthmatic
PEFR at least 75% predicted
Diurnal variation <25%
No nebs for 24 hours
Written asthma action plan
Follow up in next 30 days
Potential triggers for IPF
Genetic predisposition
Acid reflux
Viruses - EBV, herpes, hep C
Dust, textiles, cattle farming
Clinical features of IPF
SOB
Cough
Fatigue
Cyanosis
Finger clubbing
Fine end inspiratory crackles
Signs of steroid use
Look for differential diagnosis:
- joint deformity in RA
- evidence of systemic sclerosis
- skin discolouration if amiodarone
Differential diagnosis for end insp crackles
Pulmonary fibrosis (I, AACD)
* Idiopathic eg aute interstitial pneumonia (rapidly progression idiopathic pulmonary fibrosis)
* Aspiration / asbesdosis
* Connective tissue (RA / systemic sclerosis)
* Drugs (amiodarone, bleomycin, nitrofurantoin, methotrexate, sulfasalazine)
Assessment/ diagnosis of IPF
Bedside:
Lung function tests - FEV1/FVC >0.8, low TLC, reduced TLco and Kco
Bloods
ABG (hypoxia)
Autoantibodies
- ANA - elevated in 10-20%
- RA - elevated in 10-20%
- Anti CCP - normal
Secretions
- Bronchoalveolar lavage
- exclude infection prior to immunosuppression
- if lymphocytes > neuts likely better response to steroids
Radiology
- CXR- small lung volumes, interstitial shadowing most marked at bases and peripheries
- HRCT
Extras
- Lung biopsy
Management of IPF
Pulmonary rehab
Antifibrotic drugs eg. Pirfenidone
LTOT
Lung transplant
Causes of basal fibrosis
I, AACD
Idiopathic pulmonary fibrosis
Asbestosis / Asbestosis
Connective tissue diseases (apart from ank spond)
Drugs - nitrofurantoin, bleomycin, amiodarone
Clinical signs of cystic fibrosis
Clubbing
Wet cough
Hyperinflated lungs reduced chest expansion
Coarse inspiratory crackles and wheeze
Portacath
PEG
What are the genetics of cystic fibrosis
Incidence of 1/2500 live births
Autosomal recessive chromosome 7q
Gene encodes CFTR (Cl- channel)
What is the Pathophysiology of cystic fibrosis
Secretions are thickens and block the lumens of various structures causing:
- bronchiectasis
- diabetes and loss of pancreatic exocrine function
- distal intestinal obstruction syndrome
- absence of vas deferens in males causing infertility
- subfertility in women due to affect of fallopian tubes
How is cystic fibrosis diagnosed
Screening with heel prick test (low immunoreative trypsin)
Sweat test (Na > 60mmol)
Genetic testing
CXR
CT
How is cystic fibrosis managed?
MDT approach
- Physiotherapy / OT / Social worker
- Chest physio at home / cough assist
- Patient education - avoid mixing (share pathogens)
- Psychologist
- Managed by specialist CF team
- Immunisations
Respiratory
- Antibiotics - both prophylactic and treatment
- Mucolytics - ?carbocystine / saline nebs
- Lung transplant
- Poor prognosis if becomes infected with Burkholderia cepacia (can’ have lung transplant)
GIT
- Monitor for diabetes
- Pancrease and fat- soluble vitamins
Reproduction
- Genetic counselling
- Education about sub fertility / infertility
Gene therapy is an ongoing area of research